<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752540</url>
  </required_header>
  <id_info>
    <org_study_id>F901318-01-16</org_study_id>
    <nct_id>NCT04752540</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment</brief_title>
  <official_title>A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F2G Biotech GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>F2G Biotech GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single oral dose study to investigate the PK and safety of olorofim in mild and moderately&#xD;
      hepatically impaired subjects compared to subjects with normal hepatic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the time of the last quantifiable concentration (AUC 0-t)</measure>
    <time_frame>0-96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0-96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>0-96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half Life (t1/2)</measure>
    <time_frame>0-96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf)</measure>
    <time_frame>0-96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg olorofim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 to 120 mg olorofim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>120 mg olorofim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olorofim</intervention_name>
    <description>single oral dose</description>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <other_name>F901318</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects 18 to 70 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Body weight ≥50 kg and BMI within the range 18 to 35 kg/m2 (inclusive&#xD;
&#xD;
          -  Subjects with mild hepatic impairment will have grade A Child-Pugh score of 5 to 6 at&#xD;
             screening and Day -1:&#xD;
&#xD;
          -  Subjects with moderate hepatic impairment: will have grade B Child-Pugh score of 7 to&#xD;
             9 at screening and Day -1&#xD;
&#xD;
          -  Subjects with normal liver function must be in good health, as determined by a medical&#xD;
             history, physical examination, vital signs, 12-lead ECG, and clinical laboratory&#xD;
             evaluations&#xD;
&#xD;
          -  Subjects with normal liver function are matched by gender, age (±10 years) and BMI (±&#xD;
             20%) to at least one hepatically impaired subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have an abnormality in the 12-lead ECG that, in the opinion of the&#xD;
             Investigator, increases the risk of participating in the study&#xD;
&#xD;
          -  Subjects with any history of convulsion (other than childhood febrile convulsion&#xD;
             before the age of 6 years).&#xD;
&#xD;
          -  Subjects who have any clinically significant allergic disease (excluding mild or&#xD;
             seasonal allergies such as contact dermatitis or hay fever) as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Subjects with a history of or any concomitant active malignancy.&#xD;
&#xD;
          -  Subjects with a history of drug or alcohol abuse.&#xD;
&#xD;
          -  Subjects with, or with a history of, any clinically significant neurological, renal,&#xD;
             cardiovascular, psychiatric, respiratory, metabolic, endocrine, ocular (including&#xD;
             minor trauma), hematological, or other major disorders as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Subjects with signs or symptoms consistent with a COVID-19 infection at screening or&#xD;
             Day -1&#xD;
&#xD;
          -  Hepatically impaired subjects with liver transplantation, autoimmune liver disease, or&#xD;
             drug-induced liver damage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Cornelissen</last_name>
    <phone>+44 (0 161 7851270</phone>
    <email>kcornelissen@f2g.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orange County Research Centre</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joel Neutel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Centre</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas C Marbury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olorofim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

